Sexual Health

PT-141 Dosing & Reconstitution Calculator

Melanocortin receptor agonist (Bremelanotide) for sexual dysfunction. FDA-approved Vyleesi dose: 1.75 mg SQ.

TL;DR - PT-141 is a sexual health peptide with a typical starting dose of 1.75 mg. For a 10 mg vial, add 2 mL bacteriostatic water to yield 5 mg/mL.
1.75 mg
Start Dose
10 mg
Vial
2 mL
BAC Water
5
mg/mL
1.75 mg draw on a 100-unit insulin syringe
010203040506070809010035 IUascendpeptide.org
Compare Similar
This Peptide
PT-141
1.75 mg start
Kisspeptin-10
100 µg start
Coming soon
Oxytocin
10 µg start
Coming soon
Track PT-141 in Protocol Tracker
Frequently Asked
How do I reconstitute PT-141?
Add 2 mL of bacteriostatic water to a 10 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 5 mg/mL.
What is the recommended dose of PT-141?
A typical research dose is 1.75 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a PT-141 vial?
A 10 mg vial reconstituted with 2 mL BAC water yields approximately 5 doses at 1.75 mg each.
How many IU is 1.75 mg of PT-141 on a syringe?
With a 10 mg vial reconstituted in 2 mL bacteriostatic water, the concentration is 5 mg/mL. For a 1.75 mg dose: Volume = 1.75 mg ÷ 5 mg/mL = 0.35 mL. Draw to the 35 line on a 100-unit insulin syringe. You can adjust these values in the ASCEND calculator for any vial size.
What does a PT-141 dosage calculator do?
A PT-141 dosage calculator converts your vial size and BAC water volume into an exact syringe draw in IU. Enter your vial strength (10 mg), reconstitution volume (2 mL), and target dose to get the precise line to draw on an insulin syringe.
What is the PT-141 reconstitution calculator formula?
Draw volume (mL) = Dose (mg) divided by Concentration (mg/mL). For a 10 mg vial with 2 mL BAC water: concentration = 5 mg/mL. For a 1.75 mg dose, the ASCEND calculator gives the exact IU line on your syringe instantly.
Peptide Intelligence
What is the mechanism of PT-141?
PT-141 activates melanocortin receptors MC3R and MC4R in the CNS hypothalamus to increase sexual arousal and motivation. Unlike PDE5 inhibitors, PT-141 acts centrally on desire and arousal pathways rather than peripherally on vascular blood flow.
What is the half-life of PT-141?
PT-141 has a half-life of approximately 2.7 hours. Effects typically begin within 45–60 minutes of subcutaneous injection and last 4–12 hours. The FDA-approved form (Vyleesi) is injected subcutaneously into the abdomen or thigh 45 minutes before anticipated activity.
What is PT-141 FDA-approved for?
PT-141 (Bremelanotide / Vyleesi) received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only approved centrally-acting sexual dysfunction treatment. Off-label research explores its use in men with erectile dysfunction and low libido.
Primary Sources
FDA Label (Vyleesi) HSDD Phase 3 (J Sex Med 2019)
Data last reviewed 2026-06-03 · Methodology →
Cite This Calculator